ONCO Stock Overview
A biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Oncopeptides AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 2.09 |
| 52 Week High | SEK 9.40 |
| 52 Week Low | SEK 2.00 |
| Beta | -0.39 |
| 11 Month Change | -3.92% |
| 3 Month Change | -20.27% |
| 1 Year Change | -70.34% |
| 33 Year Change | -67.92% |
| 5 Year Change | -98.17% |
| Change since IPO | -95.15% |
Recent News & Updates
Recent updates
An Intrinsic Calculation For Oncopeptides AB (publ) (STO:ONCO) Suggests It's 45% Undervalued
Jun 18
Oncopeptides (STO:ONCO) Will Have To Spend Its Cash Wisely
Feb 29Oncopeptides (STO:ONCO) Has Debt But No Earnings; Should You Worry?
Nov 14We Think Oncopeptides (STO:ONCO) Needs To Drive Business Growth Carefully
Jul 26Is Oncopeptides (STO:ONCO) In A Good Position To Invest In Growth?
Mar 25Is Oncopeptides (STO:ONCO) In A Good Position To Invest In Growth?
Nov 23Shareholder Returns
| ONCO | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -1.7% | 3.5% | -0.2% |
| 1Y | -70.3% | 36.9% | 28.4% |
Return vs Industry: ONCO underperformed the Swedish Biotechs industry which returned 34% over the past year.
Return vs Market: ONCO underperformed the Swedish Market which returned 25.7% over the past year.
Price Volatility
| ONCO volatility | |
|---|---|
| ONCO Average Weekly Movement | 6.7% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in SE Market | 11.4% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: ONCO has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: ONCO's weekly volatility has decreased from 12% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 67 | Sofia Heigis | www.oncopeptides.com/sv |
Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company also engages in the research for small popypeptide based killer engages for the treatment of RRMM and hematological or solid tumors; and other peptide-drug conjugates for glioblastoma and hematological or solid tumors.
Oncopeptides AB (publ) Fundamentals Summary
| ONCO fundamental statistics | |
|---|---|
| Market cap | SEK 448.66m |
| Earnings (TTM) | -SEK 262.70m |
| Revenue (TTM) | SEK 21.37m |
21.0x
P/S Ratio-1.7x
P/E RatioIs ONCO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ONCO income statement (TTM) | |
|---|---|
| Revenue | SEK 21.37m |
| Cost of Revenue | SEK 119.00k |
| Gross Profit | SEK 21.25m |
| Other Expenses | SEK 283.95m |
| Earnings | -SEK 262.70m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 07, 2024
| Earnings per share (EPS) | -1.22 |
| Gross Margin | 99.44% |
| Net Profit Margin | -1,229.36% |
| Debt/Equity Ratio | 59.5% |
How did ONCO perform over the long term?
See historical performance and comparison